Else-Marie Løberg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Else-Marie Løberg has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Kenneth Hugdahl
Department of Biological and Medical Psychology University of Bergen Bergen Norway
6 shared publications - Hugo A. Jørgensen
Department of Clinical Medicine, Section of Psychiatry, Faculty of Medicine and Dentistry, University of Bergen, Norway
5 shared publications - Rune Andreas Kroken
Division of Psychiatry, Haukeland University Hospital, Bergen, Norway
5 shared publications Hugo A. Jørgensen
Department of Clinical Medicine, University of Bergen, Bergen, Norway
4 shared publicationsErik Johnsen
Division of Psychiatry, Haukeland University Hospital , Bergen , Norway ; Department of Clinical Medicine, University of Bergen , Bergen , Norway
3 shared publications- Erik Johnsen
Division of Psychiatry, Haukeland University Hospital, Bergen, Norway
3 shared publications
Latest Publications
- Open Access
Positive relation between arcuate fasciculus white matter fiber structure and severity of auditory hallucinations: A DTI tractography study
The arcuate fasciculus (AF) has been implicated in the pathology behind schizophrenia and auditory verbal hallucinations (AVHs). White matter tracts forming the arcuate fasciculus can be quantified and visualized using diffusion tensor imaging (DTI) tractography. Although there have been a number of studies on this topic, the results have been conflicting. Studying the underlying white matter structure of the AF could shed light on functional connectivity between temporal and frontal language areas in AVHs. The participants were 66 patients with a schizophrenia diagnosis, where AVHs were defined from the Positive and Negative Syndrome Scale (PANSS), and compared with a healthy control group. DTI was performed on a 3T MR scanner, and tensor estimation was done using deterministic streamline tractography. Statistical analysis of the data showed significantly longer tracts along the AF in patients with severe and frequent AVHs, as well as an overall significant asymmetry with longer fibers on the left side. In addition, there were significant positive correlations between PANSS scores and tract length, tract volume, and number of streamlines for the posterior AF segment on the left side. It is concluded that the present structural results complement previous functional findings of fronto-temporal connectivity in AVH patients.
Open AccessPositive relation between arcuate fasciculus white matter fiber structure and severity of auditory hallucinations: A DTI tractography study
The arcuate fasciculus (AF) has been implicated in the pathology behind schizophrenia and auditory verbal hallucinations (AVHs). White matter tracts forming the arcuate fasciculus can be quantified and visualized using diffusion tensor imaging (DTI) tractography. Although there have been a number of studies on this topic, the results have been conflicting. Studying the underlying white matter structure of the AF could shed light on functional connectivity between temporal and frontal language areas in AVHs. The participants were 66 patients with a schizophrenia diagnosis, where AVHs were defined from the Positive and Negative Syndrome Scale (PANSS), and compared with a healthy control group. DTI was performed on a 3T MR scanner, and tensor estimation was done using deterministic streamline tractography. Statistical analysis of the data showed significantly longer tracts along the AF in patients with severe and frequent AVHs, as well as an overall significant asymmetry with longer fibers on the left side. In addition, there were significant positive correlations between PANSS scores and tract length, tract volume, and number of streamlines for the posterior AF segment on the left side. It is concluded that the present structural results complement previous functional findings of fronto-temporal connectivity in AVH patients.
- Open Access
- 14 March 2016
- Published by Springer Nature in BMC Psychiatry
- Vol. 16 (1) , 60
The serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis
Inflammatory processes have been implicated in the etiology of schizophrenia and related psychoses, in which cognitive deficits represent core symptoms. The aim of the present study was to investigate possible associations between the level of the inflammation marker C-reactive protein (CRP) and cognitive performance in patients through the acute phase of psychosis. A total of 124 patients were assessed at admittance to hospital and 62 patients were retested at discharge or after 6 weeks at the latest, with measurements of the CRP levels and alternative forms of the Repeatable Battery for the Assessment of Neuropsychological Status. There was an inverse relationship between overall cognitive performance and CRP level at admittance. The association increased in sub-analyses including only patients with schizophrenia. In cognitive subdomain analyses statistically significant inverse associations were found between the CRP level and Delayed memory and Attention, respectively. No associations were found between CRP level and other measures of psychopathology including psychosis symptoms, depression, or functioning. At follow-up the association between CRP level and cognition was no longer present. There was a significant increase in cognitive performance between baseline and follow-up. There was a stronger increase in overall cognition scores in patients with higher baseline CRP levels. The findings indicate that signs of inflammation may serve as a state-dependent marker of cognitive dysfunctions in acute psychosis. ClinicalTrials.gov ID; NCT00932529 , registration date: 02.07.2009
- 14 March 2016
- Published by Springer Nature in BMC Psychiatry
- Vol. 16 (1) , 60
Open AccessThe serum level of C-reactive protein (CRP) is associated with cognitive performance in acute phase psychosis
Inflammatory processes have been implicated in the etiology of schizophrenia and related psychoses, in which cognitive deficits represent core symptoms. The aim of the present study was to investigate possible associations between the level of the inflammation marker C-reactive protein (CRP) and cognitive performance in patients through the acute phase of psychosis. A total of 124 patients were assessed at admittance to hospital and 62 patients were retested at discharge or after 6 weeks at the latest, with measurements of the CRP levels and alternative forms of the Repeatable Battery for the Assessment of Neuropsychological Status. There was an inverse relationship between overall cognitive performance and CRP level at admittance. The association increased in sub-analyses including only patients with schizophrenia. In cognitive subdomain analyses statistically significant inverse associations were found between the CRP level and Delayed memory and Attention, respectively. No associations were found between CRP level and other measures of psychopathology including psychosis symptoms, depression, or functioning. At follow-up the association between CRP level and cognition was no longer present. There was a significant increase in cognitive performance between baseline and follow-up. There was a stronger increase in overall cognition scores in patients with higher baseline CRP levels. The findings indicate that signs of inflammation may serve as a state-dependent marker of cognitive dysfunctions in acute psychosis. ClinicalTrials.gov ID; NCT00932529 , registration date: 02.07.2009
- Open Access
- 18 November 2014
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 5, 159
The Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability
There is a high prevalence of cannabis use reported in non-affective psychosis. Early prospective longitudinal studies conclude that cannabis use is a risk factor for psychosis, and neurochemical studies on cannabis have suggested potential mechanisms for this effect. Recent advances in the field of neuroscience and genetics may have important implications for our understanding of this relationship. Importantly, we need to better understand the vulnerability x cannabis interaction to shed light on the mediators of cannabis as a risk factor for psychosis. Thus, the present study reviews recent literature on several variables relevant for understanding the relationship between cannabis and psychosis, including age of onset, cognition, brain functioning, family history, genetics and neurological soft signs (NSS) in non-affective psychosis. Compared with non-using non-affective psychosis, the present review shows that there seem to be fewer stable cognitive deficits in patients with cannabis use and psychosis, in addition to fewer NSS and possibly more normalized brain functioning, indicating less neurobiological vulnerability for psychosis. There are, however, some familiar and genetic vulnerabilities present in the cannabis psychosis group which may influence the cannabis pathway to psychosis by increasing sensitivity to cannabis. Furthermore, an earlier age of onset suggests a different pathway to psychosis in the cannabis-using patients. Two alternative vulnerability models are presented to integrate these seemingly paradoxical findings.
- 18 November 2014
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 5, 159
Open AccessThe Cannabis Pathway to Non-Affective Psychosis may Reflect Less Neurobiological Vulnerability
There is a high prevalence of cannabis use reported in non-affective psychosis. Early prospective longitudinal studies conclude that cannabis use is a risk factor for psychosis, and neurochemical studies on cannabis have suggested potential mechanisms for this effect. Recent advances in the field of neuroscience and genetics may have important implications for our understanding of this relationship. Importantly, we need to better understand the vulnerability x cannabis interaction to shed light on the mediators of cannabis as a risk factor for psychosis. Thus, the present study reviews recent literature on several variables relevant for understanding the relationship between cannabis and psychosis, including age of onset, cognition, brain functioning, family history, genetics and neurological soft signs (NSS) in non-affective psychosis. Compared with non-using non-affective psychosis, the present review shows that there seem to be fewer stable cognitive deficits in patients with cannabis use and psychosis, in addition to fewer NSS and possibly more normalized brain functioning, indicating less neurobiological vulnerability for psychosis. There are, however, some familiar and genetic vulnerabilities present in the cannabis psychosis group which may influence the cannabis pathway to psychosis by increasing sensitivity to cannabis. Furthermore, an earlier age of onset suggests a different pathway to psychosis in the cannabis-using patients. Two alternative vulnerability models are presented to integrate these seemingly paradoxical findings.
- 31 July 2014
- Published by Taylor & Francis in Cognitive Neuropsychiatry
- Vol. 20 (1) , 81-94
Auditory verbal hallucinations reflect stable auditory attention deficits: a prospective study
Introduction. Previous studies have shown that auditory verbal hallucinations (AVHs) in psychosis are associated with reduced verbal auditory attention. Whether this is an effect of ongoing AVH or reflects a more stable cognitive vulnerability also present after treating the AVH is unknown. The aim of this study was to follow patients with acute psychosis with and without AVH, and to test their auditory attention in a more stabilised clinical phase. Methods. Fifty patients (35 males and 15 females) were examined when admitted to an acute psychiatry ward and tested three months later with a dichotic listening test with attention instructions. The patients were divided into a frequent (n = 33) and non-frequent (n = 17) AVH group based on their score on the Positive and Negative Syndrome Scale item hallucinatory behaviour (≥4 and ≤3, respectively) at baseline. Results. A significant interaction emerged between AVH group and attention instruction condition; the frequent AVH group failed to control their auditory attention as opposed to the non-frequent AVH group. Conclusions. Patients with frequent AVH in an acute psychotic state showed impaired auditory attention three months after their AVH had been treated, indicating a stable cognitive vulnerability factor for experiencing AVH.
- 31 July 2014
- Published by Taylor & Francis in Cognitive Neuropsychiatry
- Vol. 20 (1) , 81-94
Auditory verbal hallucinations reflect stable auditory attention deficits: a prospective study
Introduction. Previous studies have shown that auditory verbal hallucinations (AVHs) in psychosis are associated with reduced verbal auditory attention. Whether this is an effect of ongoing AVH or reflects a more stable cognitive vulnerability also present after treating the AVH is unknown. The aim of this study was to follow patients with acute psychosis with and without AVH, and to test their auditory attention in a more stabilised clinical phase. Methods. Fifty patients (35 males and 15 females) were examined when admitted to an acute psychiatry ward and tested three months later with a dichotic listening test with attention instructions. The patients were divided into a frequent (n = 33) and non-frequent (n = 17) AVH group based on their score on the Positive and Negative Syndrome Scale item hallucinatory behaviour (≥4 and ≤3, respectively) at baseline. Results. A significant interaction emerged between AVH group and attention instruction condition; the frequent AVH group failed to control their auditory attention as opposed to the non-frequent AVH group. Conclusions. Patients with frequent AVH in an acute psychotic state showed impaired auditory attention three months after their AVH had been treated, indicating a stable cognitive vulnerability factor for experiencing AVH.
- Open Access
- 30 September 2013
- Published by Springer Nature in BMC Psychiatry
- Vol. 13 (1) , 241
Hallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study
Hallucinations are prevalent in schizophrenia and related psychotic disorders and may have severe consequences for the affected patients. Antipsychotic drug trials that specifically address the anti-hallucinatory effectiveness of the respective drugs in representative samples are rare. The aims of the present study were to investigate the rate and severity of hallucinations in acutely admitted psychotic patients at hospital admission and discharge or after 6 weeks at the latest, if not discharged earlier (discharge/6 weeks); and to compare the anti-hallucinatory effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone with up to 2 years’ follow-up. Adult patients acutely admitted to an emergency ward for psychosis were consecutively randomized to risperidone, olanzapine, quetiapine, or ziprasidone and followed for up to 2 years in a pragmatic design. Participants were assessed repeatedly using the hallucinatory behavior item of the Positive and Negative Syndrome Scale (PANSS). A total of 226 patients, 30.5% of those assessed for eligibility, were randomized and 68% were hallucinating at baseline. This proportion was reduced to 33% at discharge/6 weeks. In the primary analyses based on intention to treat groups of patients experiencing frequent hallucinations, the quetiapine and ziprasidone groups both had faster decreases of the mean hallucination scores than the risperidone group. Hallucinations are fairly responsive to antipsychotic drug treatment and differential anti-hallucinatory effectiveness may be found among existing antipsychotic drugs. If replicated, this could pave the way for a more targeted pharmacotherapy based on individual symptom profiles, rather than on the diagnostic category. ClinicalTrials.gov ID; NCT00932529
- 30 September 2013
- Published by Springer Nature in BMC Psychiatry
- Vol. 13 (1) , 241
Open AccessHallucinations in acutely admitted patients with psychosis, and effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone: a pragmatic, randomized study
Hallucinations are prevalent in schizophrenia and related psychotic disorders and may have severe consequences for the affected patients. Antipsychotic drug trials that specifically address the anti-hallucinatory effectiveness of the respective drugs in representative samples are rare. The aims of the present study were to investigate the rate and severity of hallucinations in acutely admitted psychotic patients at hospital admission and discharge or after 6 weeks at the latest, if not discharged earlier (discharge/6 weeks); and to compare the anti-hallucinatory effectiveness of risperidone, olanzapine, quetiapine, and ziprasidone with up to 2 years’ follow-up. Adult patients acutely admitted to an emergency ward for psychosis were consecutively randomized to risperidone, olanzapine, quetiapine, or ziprasidone and followed for up to 2 years in a pragmatic design. Participants were assessed repeatedly using the hallucinatory behavior item of the Positive and Negative Syndrome Scale (PANSS). A total of 226 patients, 30.5% of those assessed for eligibility, were randomized and 68% were hallucinating at baseline. This proportion was reduced to 33% at discharge/6 weeks. In the primary analyses based on intention to treat groups of patients experiencing frequent hallucinations, the quetiapine and ziprasidone groups both had faster decreases of the mean hallucination scores than the risperidone group. Hallucinations are fairly responsive to antipsychotic drug treatment and differential anti-hallucinatory effectiveness may be found among existing antipsychotic drugs. If replicated, this could pave the way for a more targeted pharmacotherapy based on individual symptom profiles, rather than on the diagnostic category. ClinicalTrials.gov ID; NCT00932529
- RetractionOpen Access
- 20 August 2013
- Published by Springer Nature in BMC Research Notes
- Vol. 6 (1) , 332
Erratum to: Does changing from a first generation antipsychotic (perphenazin) to a second generation antipsychotic (risperidone) alter brain activation and motor activity? A case report
- 20 August 2013
- Published by Springer Nature in BMC Research Notes
- Vol. 6 (1) , 332
RetractionOpen AccessErratum to: Does changing from a first generation antipsychotic (perphenazin) to a second generation antipsychotic (risperidone) alter brain activation and motor activity? A case report
- RetractedOpen Access
- 6 May 2013
- Published by Springer Nature in BMC Research Notes
- Vol. 6 (1) , 182
Does changing from a first generation antipsychotic (perphenazin) to a second generation antipsychotic (risperidone) alter brain activation and motor activity? A case report
In patients with schizophrenia, altered brain activation and motor activity levels are central features, reflecting cognitive impairments and negative symptoms, respectively. Newer studies using nonlinear methods have addressed the severe disturbances in neurocognitive functioning that is regarded as one of the core features of schizophrenia. Our aim was to compare brain activation and motor activity in a patient during pharmacological treatment that was switched from a first- to a second-generation antipsychotic drug. We hypothesised that this change of medication would increase level of responding in both measures.
- 6 May 2013
- Published by Springer Nature in BMC Research Notes
- Vol. 6 (1) , 182
RetractedOpen AccessDoes changing from a first generation antipsychotic (perphenazin) to a second generation antipsychotic (risperidone) alter brain activation and motor activity? A case report
In patients with schizophrenia, altered brain activation and motor activity levels are central features, reflecting cognitive impairments and negative symptoms, respectively. Newer studies using nonlinear methods have addressed the severe disturbances in neurocognitive functioning that is regarded as one of the core features of schizophrenia. Our aim was to compare brain activation and motor activity in a patient during pharmacological treatment that was switched from a first- to a second-generation antipsychotic drug. We hypothesised that this change of medication would increase level of responding in both measures.
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 4
Corrigendum: An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use
A commentary on An fMRI study of neuronal activation in schizophrenia patients with and without previous cannabis use by Løberg, E.-M., Nygård, M., Berle, J. ø., Johnsen, E., Kroken, R. A., Jørgensen, H. A., and Hugdahl, K. (2012). Front. Psychiatry 3:94. doi: 10.3389/fpsyt.2012.00094 p. 4, “MR-SCANNING” section, line 7 from bottom: The following sentence “[ … ] a high-resolution T1-weighted 3D volume image was acquired prior to the EPI image acquisitions using a FSPGR pulse sequence with 122 sagittal slices (64 × 64 matrix size, 1.0 mm slice thickness, TE = 30 ms, TR = 1500 ms, FA = 90). [ … ]” should be replaced by “[ … ] a high-resolution T1-weighted 3D volume image was acquired prior to the EPI image acquisitions using a FSPGR pulse sequence with 180 sagittal slices (256 × 256 matrix size, field of view (FoV) = 256 mm× 256 mm, 1.0 mm slice thickness, TI = 500 ms, FA = 11). [ … ]” Citation: Løberg E-M, Nygård M, Berle JØ, Johnsen E, Kroken RA, Jørgensen HA and Hugdahl K (2013) Corrigendum: An fMRI study of neuronal activation in schizophrenia patients with and without previous cannabis use. Front. Psychiatry 4:51. doi: 10.3389/fpsyt.2013.00051 Received: 13 May 2013; Accepted: 24 May 2013; Published online: 07 June 2013. Edited by: Copyright: © 2013 Løberg, Nygård, Berle, Johnsen, Kroken, Jørgensen and Hugdahl. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc. *Correspondence: hugdahl@psybp.uib.no
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 4
Open AccessCorrigendum: An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use
A commentary on An fMRI study of neuronal activation in schizophrenia patients with and without previous cannabis use by Løberg, E.-M., Nygård, M., Berle, J. ø., Johnsen, E., Kroken, R. A., Jørgensen, H. A., and Hugdahl, K. (2012). Front. Psychiatry 3:94. doi: 10.3389/fpsyt.2012.00094 p. 4, “MR-SCANNING” section, line 7 from bottom: The following sentence “[ … ] a high-resolution T1-weighted 3D volume image was acquired prior to the EPI image acquisitions using a FSPGR pulse sequence with 122 sagittal slices (64 × 64 matrix size, 1.0 mm slice thickness, TE = 30 ms, TR = 1500 ms, FA = 90). [ … ]” should be replaced by “[ … ] a high-resolution T1-weighted 3D volume image was acquired prior to the EPI image acquisitions using a FSPGR pulse sequence with 180 sagittal slices (256 × 256 matrix size, field of view (FoV) = 256 mm× 256 mm, 1.0 mm slice thickness, TI = 500 ms, FA = 11). [ … ]” Citation: Løberg E-M, Nygård M, Berle JØ, Johnsen E, Kroken RA, Jørgensen HA and Hugdahl K (2013) Corrigendum: An fMRI study of neuronal activation in schizophrenia patients with and without previous cannabis use. Front. Psychiatry 4:51. doi: 10.3389/fpsyt.2013.00051 Received: 13 May 2013; Accepted: 24 May 2013; Published online: 07 June 2013. Edited by: Copyright: © 2013 Løberg, Nygård, Berle, Johnsen, Kroken, Jørgensen and Hugdahl. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc. *Correspondence: hugdahl@psybp.uib.no
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 7
Corrigendum: Patients with schizophrenia fail to up-regulate task-positive and down-regulate task-negative brain networks: an fMRI study using an ICA analysis approach
A commentary on Patients with schizophrenia fail to up-regulate task-positive and down-regulate task-negative brain networks: an fMRI study using an ICA analysis approach by Nygård, M., Eichele, T., Løberg, E-M., Jørgensen, H. A., Johnsen, E., Kroken, R. A., et al. (2012). Front. Hum. Neurosci. 6:149. doi: 10.3389/fnhum.2012.00149 p. 4, “MR IMAGING” section, line 20 from bottom: The following sentences “[…] The T1-images were acquired with an EPI sequence. The T1-images were acquired with a FSPGR pulse sequence with 122 sagittal slices [64 × 64 matrix size, slice thickness = 1.0 mm, echo time (TE) = 30 ms, repetition time (TR) = 1.5 s, flip angle (FA) = 90]. […]” should be replaced by “[…] The T1-images were acquired with a FSPGR pulse sequence with 180 sagittal slices [256 × 256 matrix size, field of view (FoV) = 256 × 256 mm2, slice thickness = 1.0 mm, inversion time (TI) = 500 ms, flip angle (FA) = 11]. […]” Citation: Nygård M, Eichele T, Løberg E-M, Jørgensen HA, Johnsen E, Kroken RA, Berle JO and Hugdahl K (2013) Corrigendum: Patients with schizophrenia fail to up-regulate task-positive and down-regulate task-negative brain networks: an fMRI study using an ICA analysis approach. Front. Hum. Neurosci. 7:231. doi: 10.3389/fnhum.2013.00231 Received: 13 May 2013; Accepted: 14 May 2013; Published online: 30 May 2013. Edited by: Copyright © 2013 Nygård, Eichele, Løberg, Jørgensen, Johnsen, Kroken, Berle and Hugdahl. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc. *Correspondence: hugdahl@psybp.uib.no
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Human Neuroscience
- Vol. 7
Open AccessCorrigendum: Patients with schizophrenia fail to up-regulate task-positive and down-regulate task-negative brain networks: an fMRI study using an ICA analysis approach
A commentary on Patients with schizophrenia fail to up-regulate task-positive and down-regulate task-negative brain networks: an fMRI study using an ICA analysis approach by Nygård, M., Eichele, T., Løberg, E-M., Jørgensen, H. A., Johnsen, E., Kroken, R. A., et al. (2012). Front. Hum. Neurosci. 6:149. doi: 10.3389/fnhum.2012.00149 p. 4, “MR IMAGING” section, line 20 from bottom: The following sentences “[…] The T1-images were acquired with an EPI sequence. The T1-images were acquired with a FSPGR pulse sequence with 122 sagittal slices [64 × 64 matrix size, slice thickness = 1.0 mm, echo time (TE) = 30 ms, repetition time (TR) = 1.5 s, flip angle (FA) = 90]. […]” should be replaced by “[…] The T1-images were acquired with a FSPGR pulse sequence with 180 sagittal slices [256 × 256 matrix size, field of view (FoV) = 256 × 256 mm2, slice thickness = 1.0 mm, inversion time (TI) = 500 ms, flip angle (FA) = 11]. […]” Citation: Nygård M, Eichele T, Løberg E-M, Jørgensen HA, Johnsen E, Kroken RA, Berle JO and Hugdahl K (2013) Corrigendum: Patients with schizophrenia fail to up-regulate task-positive and down-regulate task-negative brain networks: an fMRI study using an ICA analysis approach. Front. Hum. Neurosci. 7:231. doi: 10.3389/fnhum.2013.00231 Received: 13 May 2013; Accepted: 14 May 2013; Published online: 30 May 2013. Edited by: Copyright © 2013 Nygård, Eichele, Løberg, Jørgensen, Johnsen, Kroken, Berle and Hugdahl. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in other forums, provided the original authors and source are credited and subject to any copyright notices concerning any third-party graphics etc. *Correspondence: hugdahl@psybp.uib.no
- Open Access
- 1 January 2012
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 3, 31422
An fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use
Previous studies have mostly shown positive effects of cannabis use on cognition in patients with schizophrenia, which could reflect lower neurocognitive vulnerability. There are however no studies comparing whether such cognitive differences have neuronal correlates. Thus, the aim of the present study was to compare whether patients with previous cannabis use differ in brain activation from patients who has never used cannabis. The patients groups were compared on the ability to up-regulate an effort mode network during a cognitive task and down-regulate activation in the same network during a task-absent condition. Task-present and task-absent brain activation was measured by functional magnetic resonance neuroimaging (fMRI). Twenty-six patients with a DSM-IV and ICD-10 diagnosis of schizophrenia were grouped into a previous cannabis user group and a no-cannabis group. An auditory dichotic listening task with instructions of attention focus on either the right or left ear stimulus was used to tap verbal processing, attention, and cognitive control, calculated as an aggregate score. When comparing the two groups, there were remaining activations in the task-present condition for the cannabis group, not seen in the no-cannabis group, while there was remaining activation in the task-absent condition for the no-cannabis group, not seen in the cannabis group. Thus, the patients with previous cannabis use showed increased activation in an effort mode network and decreased activation in the default mode network as compared to the no-cannabis group. It is concluded that the present study show some differences in brain activation to a cognitively challenging task between previous cannabis and no-cannabis schizophrenia patients.
- 1 January 2012
- Published by Frontiers Media SA in Frontiers in Psychiatry
- Vol. 3, 31422
Open AccessAn fMRI Study of Neuronal Activation in Schizophrenia Patients with and without Previous Cannabis Use
Previous studies have mostly shown positive effects of cannabis use on cognition in patients with schizophrenia, which could reflect lower neurocognitive vulnerability. There are however no studies comparing whether such cognitive differences have neuronal correlates. Thus, the aim of the present study was to compare whether patients with previous cannabis use differ in brain activation from patients who has never used cannabis. The patients groups were compared on the ability to up-regulate an effort mode network during a cognitive task and down-regulate activation in the same network during a task-absent condition. Task-present and task-absent brain activation was measured by functional magnetic resonance neuroimaging (fMRI). Twenty-six patients with a DSM-IV and ICD-10 diagnosis of schizophrenia were grouped into a previous cannabis user group and a no-cannabis group. An auditory dichotic listening task with instructions of attention focus on either the right or left ear stimulus was used to tap verbal processing, attention, and cognitive control, calculated as an aggregate score. When comparing the two groups, there were remaining activations in the task-present condition for the cannabis group, not seen in the no-cannabis group, while there was remaining activation in the task-absent condition for the no-cannabis group, not seen in the cannabis group. Thus, the patients with previous cannabis use showed increased activation in an effort mode network and decreased activation in the default mode network as compared to the no-cannabis group. It is concluded that the present study show some differences in brain activation to a cognitively challenging task between previous cannabis and no-cannabis schizophrenia patients.